ArriVent BioPharma, Inc.

For the period ended Jun 30, 2026. Filed Aug 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 12, 2026

AVBP$14.16+3.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Balance Sheets

(in thousands, except share and per share data)


· · June 30, · · December 31,
· · 2026 · · 2025
Assets · · · ·
Current assets: · · · ·
Cash and cash equivalents	$154,682	$45,540
Short-term investments	218,437	267,281
Prepaid expenses and other current assets	21,054	20,076
Total current assets	394,173	332,897
Right of use assets – operating leases	370	13
Deferred offering costs	41	69
Other assets	134	190
Total assets	$394,718	$333,169

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$2,217	$5,934
Accrued expenses	25,309	19,997
Operating lease liabilities	318	14
Total current liabilities	27,844	25,945
Operating lease liabilities, net of current amount	33	—
Total liabilities	27,877	25,945

Commitments and contingencies (Note 8)

Stockholders’ equity:
Preferred stock $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding	—	—
Common stock $0.0001 par value, 200,000,000 shares authorized; 48,319,591 and 42,452,251 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	5	4
Additional paid-in capital	864,957	711,847
Accumulated deficit	(497,854)	(404,641)
Accumulated other comprehensive income (loss)	(267)	14
Total stockholders’ equity	366,841	307,224
Total liabilities and stockholders’ equity	$394,718	$333,169

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.